

DAFTAR PUSTAKA

- Allredge, B.K., Affairs, A., Francisco, S., Francisco, S., Corelli, R.L., Francisco, S., Francisco, S., Ernst, M.E., City, I., Guglielmo, B.J., Francisco, S., Francisco, S., Jacobson, P.A., Pharmacology, C., Kradjan, W.A., Emeritus, D., Health, O., Williams, B.R., Gerontology, C. & Economics, P, 2013, *Applied therapeutics: The clinical use of drugs*, 10th edition, Lippincott Williams & Wilkins, Philadelphia.
- American Psychiatric Association, 2000, *Diagnostic and Statistical Manual of Mental Disorder*, 4th edition, 297–319, American Psychiatric Publishing, Washington DC.
- Anonim, 2019, *Clozapine Monograph*, https://www-clinicalkey-com.ezproxy.ugm.ac.id/#!/content/drug_monograph/6-s2.0-142?scrollTo=%23Indications, 13 Maret 2020.
- Anonim, 2020, *Risperidone Monograph*, https://www-clinicalkey-com.ezproxy.ugm.ac.id/#!/content/drug_monograph/6-s2.0-549?scrollTo=%23AdverseReactions, 13 Maret 2020.
- AphA, 2009, *Drug Information Handbook*, 21st edition, Lexicomp, Ohio.
- Aryani, F. & Sari, O, 2016, Gambaran Pola Penggunaan Antipsikotik pada Pasien Skizofrenia di Ruang Rawat Inap Rumah Sakit Jiwa, *Jurnal Manajemen dan Pelayanan Farmasi*, Volume 6 N: 35–40.
- Baxter, K, 2006, *Stockley's Drug Interactions*, 7th Edition, London.
- De Berardis, D., Gabriella, R. & Olivieri, L, 2018, Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine, *Therapeutic Advances in Drug Safety*, 9(6): 237–256.
- Berman, B.D, 2011, Neuroleptic Malignant Syndrome : A Review for Neurohospitalists. 1(1): 41–47.
- Brinster, N, 2012, Cutaneous adverse reactions to drugs, *McKee's Pathology of the Skin*, 590–630.
- Buthcer, J.N., Mineka, S. & Hooley, J.M, 2013, *Abnormal Psychology*, 15th edition, Pearson Education, Inc, USA
- Crismon, M.L., Argo, T.R. & Buckley, P, 2015, 'Schizophrenia', dalam *Pharmacotherapy : A Pathophysiologic Approach*, 9th edition, McGraw-Hill Education, New York.
- Dayabandara, M., Hanwella, R., Ratnatunga, S., Seneviratne, S., Suraweera, C. & de Silva, V.A, 2017, Antipsychotic-associated weight gain : management strategies and impact on treatment adherence, *Neuropsychiatric Disease and Treatment*, 2231–2241.

- Departemen Kesehatan RI, 2018, *Riset Kesehatan Dasar 2018*, Departemen Kesehatan RI, Jakarta.
- Divac, N., Prostran, M., Jakovcevski, I. & Cerovac, N, 2014, *Extrapyramidal Adverse Effects*.
- Girardin, F. & Sztajzel, J, 2007, *Cardiac adverse reactions associated with psychotropic drugs*, 92–95.
- Halgin, R.P. & Whitbourne, S.K, 2006, *Abnormal psychology: clinical perspectives on psychological disorders*, 5th edition, McGraw-Hill, New York.
- International Diabetes Federation, 2006, *The IDF Consensus Worldwide Definition of The Metabolic Syndrome*.
- Iqbal, M.M., Rahman, A., Husain, Z., Mahmud, S.Z., Ryan, W.G. & Feldman, J.M, 2003, *Clozapine : A Clinical Review of Adverse Effects*, 15(1).
- Iverson, S., Kautiainen, A., Ip, J. & Uetrecht, J.P, 2010, Effect of clozapine on neutrophil kinetics in rabbits. *Chemical Research in Toxicology*, 23(7): 1184–1191.
- Jeon, S.W. & Kim, Y, 2017, Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia : Antipsychotic Polypharmacy and Metabolic Syndrome. *International Journal of Molecular Sciences*, 18(2174).
- Lally, J. & MacCabe, J.H, 2015, Antipsychotic medication in schizophrenia: A review. *British Medical Bulletin*, 114(1): 169–179.
- Li, R., Wang, G., Yang, J. & Wang, C, 2017, Why sex differences in schizophrenia ?, 1(1): 37–42.
- Liu, X., Wu, Z., Lian, J., Hu, C.H., Huang, X.F. & Deng, C, 2017, Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats, *Scientific Reports*, 7(1): 1–13.
- De Luca, V., Mueller, D.J., de Bartolomeis, A. & Kennedy, J.L, 2007, Association of the HTR2C gene and antipsychotic induced weight gain: ameta-analysis, *International Journal Neuropsychopharmacol*, (10): 697–704.
- Martín Conde, M.T, 2005, [Drug related problems], *Medicina clinica*, 124(7): 261–2.
- McDonagh, M., Dana, T., Selph, S. & Devine, E.B, 2017, *Treatments for Schizophrenia in Adults : A Systematic Review*, AHRQ Publication, Portland.
- Meyler, L, 2016, *Meyler's Side Effects of Drugs*, 16th edition, 443–477, Elsevier, Oxford.

- Miller, B.J. & Buckley, P.F, 2019, *Conn's Current Therapy*, 787–791, Elsevier, Oxford.
- Mueser, K.T. & Jeste, D. V, 2008, *Clinical Handbook Of Schizophrenia*.
- Mukaddas, A. & Faustine, I, 2014, Rasionalitas Penggunaan Antipsikotik pada Pasien Skizofrenia di Instalasi Rawat Inap Jiwa RSD Madani Provinsi Sulawesi Tengah Periode Januari-April 2014, *Online Jurnal of Natural Science*, 3(2): 18–29.
- Ng, W., Kennar, R. & Uetrecht, J, 2014, Effect of clozapine and olanzapine on neutrophil kinetics: Implications for drug-induced agranulocytosis, *Chemical Research in Toxicology*, 27(7): 1104–1108.
- Nugroho, A.E, 2011, *Farmakologi*, Pustaka Pelajar, Yogyakarta.
- Owen, M.J., Sawa, A. & Mortensen, P.B, 2017, *Schizophrenia*, HHS Public Access.
- Ozdemir, V., Masellis, M., Basile, V., Kalow, W., Meltzer, H., Lieberman, J.A. & Kennedy, J., 2009, Variability in response to clozapine: potential role of cytochrome P450 1A2 and the dopamine D4 receptor gene, *CNS spectrums*, 4(6).
- Porrás-segovia, A., Krivoy, A., Horowitz, M., Thomas, G., Bolstridge, M., Ion, D. & Shergill, S.S, 2017, Rapid-onset clozapine-induced loss of glycaemic control : case report, *BJPsych Open*, 138–140.
- Preston, C.L, 2019, *Stockley's Drug Interaction*, 12th edition, Pharmaceutical Press, London.
- Qiu, H., He, Y., Zhang, Y., He, M., Liu, J., Chi, R., Si, T., Wang, H. & Dong, W, 2018, Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan, *Australian and New Zealand Journal of Psychiatry*, 52(12): 1202–1212.
- Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C.A., Kissling, W., Davis, J.M. & Leucht, S, 2010, Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis, *Schizophrenia Research*, 123(2–3): 225–233.
- Sadock, B.J. & Sadock, V.A, 2015, *Kaplan & Sadock's Synopsis of Psychiatry : Behavioral Sciences/Clinical Psychiatry*, 11th edition, Wolters Kluwer, Philadelphia.
- Shargel, L., Wu-Pong, S. & Yu, A.B.C, 2005, *Biofarmasetika dan Farmakokinetika Terapan*, Airlangga University Press, Surabaya.
- Sicard, M., Zai, C.C., Tiwari, A.K., Souza, R., Meltzer, H.Y., Lieberman, D.J., Kennedy, J.L. & Muller, D.J, 2010, Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain : an update and meta-analysis,

Pharmacogenomics, (11): 1561–1571.

Tatro, D.S, 2015, *Drug Interaction Facts*, Wolters Kluwer Health Inc, California

Vancampfort, D., Sweers, K., Winkel, R. Van, Yu, W. & Hert, M. De, 2013, Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders — A Systematic Review and Meta-Analysis, 39(2): 306–318.

Ventriglio, A., Baldessarini, R.J., Vitrani, G., Bonfitto, I., Cecere, A.C., Rinaldi, A., Petito, A. & Bellomo, A, 2019, Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics.

Yuen, J.W.Y., Wu, C., Wang, C.K., Kim, D.D., Procyshyn, R.M., Honer, W.G. & Barr, A.M, 2019, A comparison of the effects of clozapine and its metabolite norclozapine on metabolic dysregulation in rodent models, *Neuropharmacology*.

Yulianty, M.D., Cahaya, N. & Srikartika, V.M, 2017, Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan, *Jurnal Sains Farmasi & Klinis*, 3(2): 153.

Zahnia, S. & Wulan Sumekar, D, 2016, Kajian Epidemiologis Skizofrenia. *Majority*, 5(5): 160–166.